Viewing Study NCT03682068

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:48 PM
Ignite Modification Date: 2026-01-02 @ 9:23 AM
Study NCT ID: NCT03682068
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-06
First Post: 2018-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Unresectable Locally Advanced Urothelial Cancer View
None Metastatic Urothelial Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None renal pelvis View
None ureters View
None urinary bladder View
None urethra View
None bladder cancer View